BACKGROUND: The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. METHODS:HIV-infected children 2-<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4-5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14 (PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of ≥ 0.5 mcg/mL of serotype-specific antibody on day 0 or change from <0.5 mcg/mL to ≥ 0.5 mcg/mL between day 0 and week 1, or, ≥ 4-fold antibody rise between day 0 and week 1. RESULTS: Prior to boosting, 4-5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46 mcg/mL (serotype 1), 1.31 mcg/mL (serotype 6B), and 1.47 mcg/mL (serotype 14), with concentrations ≥ 0.5 mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration ≥ 0.5 mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42-61% for serotype 1 and 87-94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 ≥ 4-fold antibody rise (serotype 1, 3-13%; serotype 6B, 13-31%; serotype 14, 29-53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5-0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age. CONCLUSIONS:Protective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4-5 years after PCV7-PCV7-PPV in HIV-infected children on HAART.
RCT Entities:
BACKGROUND: The capacity of pneumococcal vaccination to confer memory in HIV-infectedchildren is critical for durable protection. METHODS:HIV-infectedchildren 2-<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4-5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14 (PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of ≥ 0.5 mcg/mL of serotype-specific antibody on day 0 or change from <0.5 mcg/mL to ≥ 0.5 mcg/mL between day 0 and week 1, or, ≥ 4-fold antibody rise between day 0 and week 1. RESULTS: Prior to boosting, 4-5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46 mcg/mL (serotype 1), 1.31 mcg/mL (serotype 6B), and 1.47 mcg/mL (serotype 14), with concentrations ≥ 0.5 mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration ≥ 0.5 mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42-61% for serotype 1 and 87-94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 ≥ 4-fold antibody rise (serotype 1, 3-13%; serotype 6B, 13-31%; serotype 14, 29-53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5-0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age. CONCLUSIONS: Protective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4-5 years after PCV7-PCV7-PPV in HIV-infectedchildren on HAART.
Authors: Vana I Spoulou; Dimitris L Tsoumas; Vana G Papaevangelou; Glykeria I Mostrou; Maria C Theodoridou Journal: AIDS Date: 2003-06-13 Impact factor: 4.177
Authors: Kehmia Titanji; Angelo De Milito; Alberto Cagigi; Rigmor Thorstensson; Sven Grützmeier; Ann Atlas; Bo Hejdeman; Frank P Kroon; Lucia Lopalco; Anna Nilsson; Francesca Chiodi Journal: Blood Date: 2006-04-27 Impact factor: 22.113
Authors: Vana I Spoulou; Dimitris L Tsoumas; Vana G Papaevangelou; Glykeria I Mostrou; Maria C Theodoridou Journal: Vaccine Date: 2005-06-21 Impact factor: 3.641
Authors: Brendan Flannery; Richard T Heffernan; Lee H Harrison; Susan M Ray; Arthur L Reingold; James Hadler; William Schaffner; Ruth Lynfield; Ann R Thomas; Jianmin Li; Michael Campsmith; Cynthia G Whitney; Anne Schuchat Journal: Ann Intern Med Date: 2006-01-03 Impact factor: 25.391
Authors: Mark J Abzug; Stephen I Pelton; Lin-Ye Song; Terence Fenton; Myron J Levin; Sharon A Nachman; William Borkowsky; Howard M Rosenblatt; John F Marcinak; Arry Dieudonne; Elaine J Abrams; Indu Pathak Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Shabir A Madhi; Locadiah Kuwanda; Clare Cutland; Anne Holm; Helena Käyhty; Keith P Klugman Journal: Pediatr Infect Dis J Date: 2005-05 Impact factor: 2.129
Authors: Mark J Abzug; Min Qin; Myron J Levin; Terence Fenton; Judy A Beeler; William J Bellini; Susette Audet; Sun Bae Sowers; William Borkowsky; Sharon A Nachman; Stephen I Pelton; Howard M Rosenblatt Journal: J Infect Dis Date: 2012-06-12 Impact factor: 5.226
Authors: David Tarragó; Julio Casal; Jesús Ruiz-Contreras; J Tomás Ramos; Pablo Rojo; Harm Snippe; Wouter T M Jansen Journal: Clin Diagn Lab Immunol Date: 2005-01
Authors: Alexandria E-B Rossheim; Anna Marie P Young; Julia Siik; Tina D Cunningham; Stephanie B Troy Journal: Hum Vaccin Immunother Date: 2016-05-12 Impact factor: 3.452